# Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers

> **NCT06188624** · PHASE1 · RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.** · enrollment: 150 (estimated)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** TQB2922 for injection

## Key facts

- **NCT ID:** NCT06188624
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-01
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06188624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06188624, "Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06188624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*